Alector Announces Appointment of Elizabeth A. Garofalo, M.D., to its Board of Directors
September 28, 2021 08:30 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the addition of...
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL001 in Amyotrophic Lateral Sclerosis (ALS)
September 09, 2021 08:30 ET
|
Alector, Inc.
Randomized, placebo-controlled Phase 2 trial will enroll patients with C9orf72-associated ALS SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a...
Alector Provides Executive Leadership Update
September 07, 2021 16:30 ET
|
Alector, Inc.
Planned Transitions Announced for Shehnaaz Suliman, M.D., MBA, MPhil, President and Chief Operating Officer and Robert Paul, M.D., Ph.D., Chief Medical Officer Sam Jackson, M.D., MBA, Appointed...
Alector to Present at Upcoming Virtual Healthcare Conferences
September 02, 2021 07:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will...
Alector Reports Second Quarter 2021 Financial Results
August 03, 2021 17:09 ET
|
Alector, Inc.
Presented twelve-month data from ongoing AL001 open-label Phase 2 study in FTD-GRN at the 2021 Alzheimer’s Association International Conference (AAIC) Announced global collaboration...
Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation
July 29, 2021 10:10 ET
|
Alector, Inc.
AL001 Successfully Restored Progranulin to Normal Levels in FTD-GRN Patients Treatment with AL001 Slowed Clinical Progression by 47% Based on the CDR® plus NACC FTLD-SB Scale Relative to GENFI2...
Alector to Present New Data from Frontotemporal Dementia and Alzheimer’s Disease Programs at the 2021 Alzheimer’s Association International Conference
July 21, 2021 16:35 ET
|
Alector, Inc.
Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRNCompany to Host Analyst and Investor Conference Call on July 29 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif.,...
Alector and GSK announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases
July 02, 2021 07:38 ET
|
Alector, Inc.
Alector and GSK to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral sclerosis,...
Alector to Present at Upcoming Virtual Healthcare Conferences
June 03, 2021 16:05 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz...
Alector to Host Virtual Key Opinion Leader Event on Frontotemporal Dementia on June 11, 2021
May 26, 2021 16:05 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it will host a...